Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL21682507 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PTGS1PTGS2 | |
| SCHEMBL23924222 | 0.89 | ALDH1A1 (0.34) | ALDH1A1PTGS1PTGS2 | |
| SCHEMBL636113 | 0.88 | PTGS2 (0.38) | PTGS1PTGS2 | |
| SCHEMBL398591 | 0.88 | PTGS2 (0.38) | PTGS1PTGS2 | |
| SCHEMBL398399 | 0.88 | PTGS2 (0.38) | PTGS1PTGS2 | |
| SCHEMBL13216744 | 0.83 | PTGS1 (0.37) | ALDH1A1PTGS1PTGS2 | |
| SCHEMBL23927587 | 0.79 | PTGS2 (0.39) | PTGS1PTGS2 | |
| SCHEMBL13685896 | 0.79 | PTGS2 (0.39) | PTGS1PTGS2 | |
| SCHEMBL29830766 | 0.77 | PTGS1 (0.32) | ALDH1A1PTGS1PTGS2 | |
| SCHEMBL3239231 | 0.77 | PTGS2 (0.35) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | claimed |
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | NICOX S.A. (FR) | 2024-05-14 | — | — | US | disclosed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | PDE5A, PDE3A, PDE3B | ALDH1A1 677/4885PTGS1 42/4885PTGS2 55/4885 |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | ALDH1A1 397/4885PTGS1 36/4885PTGS2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.